CASP3 and in situ carcinoma: Our results revealed a significant (p ≤ 0.001) (p ≤ 0.05) (p ≤ 0.0001) upregulation of caspase-3 gene expression following treatment with CIS and EQ alone and in combination, respectively with the highest expression in the combined group as compared to untreated EAC group.